Nachrichten zur BioArctic AB Aktie

Long-term treatment data for lecanemab to be presented at AAIC 2024

Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will present the…

Leqembi approved for the treatment of Alzheimer’s disease in Israel

Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic…

Number of shares and votes in BioArctic AB (publ) as of June 28, 2024

Stockholm, June 28, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during June issued…

FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease

Stockholm, Sweden, June 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that that the…

Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea

Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry of Food…

Bulletin from the Annual General Meeting in BioArctic AB (publ)

Stockholm, 22 May 2024. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today,…

Interim Report for the period January – March 2024

First BrainTransporter technology agreement signed Events during the first quarter 2024 · Leqembi® was approved for the treatment of Alzheimers…

Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)

Stockholm, Sweden, May 15, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today said that they expect…

Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing

Stockholm, Sweden, May 15, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have…

Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024

Stockholm, Sweden, April 24, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

Stockholm, Sweden, April 20, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai…

Notice of Annual General Meeting in BioArctic AB (publ)

The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held…

AAX Biotechs Technology to be Utilized in BioArctic’s Research Project

Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is excited to announce that BioArctic AB, a…

The Nomination Committees proposal for the election of Board members and Chairperson of the Board in BioArctic AB

Stockholm April 16, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic…

BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm

Stockholm, Sweden, April 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) commitment to its Sustainable Innovation approach –…

Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed

Stockholm, Sweden, April 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has…

Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons

Stockholm, Sweden March 22, 2024 – BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral…

Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease

Stockholm, Sweden, March 19, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctics founder, Professor Lars…